Among the breast cancer subtypes, HER2-enriched (HER2+) and triple-negative primary tumors show higher rates of brain relapse relative to hormone receptor-positive tumors [3,4], suggesting that some innate feature(s) of primary tumor cells may dictate the development of brain metastases. This evidence concerns the gene ERBB2 and breast cancer.